Efficacy and Safety of a Cutaneous Formulation of Gonyautoxin 2/3 (GTX 2/3) for the Treatment of Facial Wrinkles

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00734786
Recruitment Status : Withdrawn (Study cancelled.)
First Posted : August 14, 2008
Last Update Posted : August 25, 2008
Information provided by:
Phytotox SA

Brief Summary:

The main objective of the trial is to determine whether the current topical formulation of GTX 2/3 reduces the wrinkling of the skin (crow's feet) after a single application

Other evaluation criteria include: safety assessment and local tolerance, depth of facial wrinkles (video microscopy imaging).

Condition or disease Intervention/treatment Phase
Facial Wrinkles Other: Wrinkle cream application Phase 1 Phase 2

Detailed Description:
This is a single volunteer group study. Each volunteer will be her own control. A volunteer will receive the active product containing cream on one side of her face and will receive the placebo cream on the other side.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of a Cutaneous Formulation of Gonyautoxin 2/3 (GTX 2/3) for the Treatment of Facial Wrinkles. Study # CLN 08-003.
Study Start Date : August 2008
Estimated Primary Completion Date : September 2008
Estimated Study Completion Date : September 2008

Arm Intervention/treatment
Placebo Comparator: 2
Volunteers will be their own control by randomly receiving the active on one face side and the placebo on the opposite one.
Other: Wrinkle cream application
Single application on the crow's feet wrinkles. Placebo cream will be applied on one side, the active cream on the other side.
Other Name: No other product will be used.

Primary Outcome Measures :
  1. Depth of facial wrinkles [ Time Frame: 24 hours ]

Secondary Outcome Measures :
  1. Local and general tolerance [ Time Frame: 1day ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   30 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Women with no bearing-child potential or with adequate birth control method.
  • Volunteers between 30 to 60 years of age.
  • Subjects with bilateral crow's feet wrinkles.
  • Regular user of cosmetic products, willing and able to comply with the study objectives.
  • Signed informed consent.

Exclusion Criteria:

  • Any medical condition or any use of a medication that could modify the study results (e.g.: NSAIDs, immunosuppressant drugs, insulin...).
  • Any other significant medical condition (e.g.: diabetes mellitus, heart disease, liver disease...).
  • Any other condition that in the investigator's opinion could not be appropriate with the participation in this trial.
  • Any health condition that could affect the evaluation of study parameters.
  • Acute or chronic skin disease.
  • History of allergic reaction to cosmetic compounds.
  • Pregnancy, planned pregnancy or breast-feeding.
  • Allergy to shellfish, fish or sea product (seaweed).
  • Known or suspected hypersensitivity to any of the study product compounds.
  • Participation in another clinical trial within 30 days previous to enrolment.
  • Known or suspected alcohol or drug abuse.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00734786

Buenos Aires, CF, Argentina
Sponsors and Collaborators
Phytotox SA
Principal Investigator: Silvia H Pérez-Damonte, PhD CLAIM

Responsible Party: Dra Silvia Pérez Damonte, CLAIM Identifier: NCT00734786     History of Changes
Other Study ID Numbers: CLN 08-003
First Posted: August 14, 2008    Key Record Dates
Last Update Posted: August 25, 2008
Last Verified: August 2008

Keywords provided by Phytotox SA:

Additional relevant MeSH terms:
Disease Attributes
Pathologic Processes